Skip to main content
SpringerLink
Log in

How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients

  • Mini Review
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21, 667–678 (2020)

    Article  PubMed  PubMed Central  Google Scholar 

  2. G. Vila, J.O.L. Jørgensen, A. Luger, G.K. Stalla, Insulin resistance in patients with acromegaly. Front Endocrinol. (Lausanne) 10, 509 (2019)

    Article  PubMed  Google Scholar 

  3. D. Cuevas-Ramos, M. Fleseriu, Pasireotide: a novel treatment for patients with acromegaly. Drug Des. Dev. Ther. 10, 227–239 (2016)

    CAS  Google Scholar 

  4. M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019)

    Article  PubMed  Google Scholar 

  5. I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667–674 (2004). p.

    Article  CAS  PubMed  Google Scholar 

  6. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)

    Article  CAS  PubMed  Google Scholar 

  7. A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, e937–e946 (2020).

  8. M. Quarella, D. Walser, M. Brändle, J.Y. Fournier, S. Bilz, Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly. J. Clin. Endocrinol. Metab. 102, 1451–1453 (2017)

    Article  PubMed  Google Scholar 

  9. N. Møller, J.O. Jørgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152–177 (2009)

    Article  PubMed  Google Scholar 

  10. S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27, 470–483 (2016)

    Article  CAS  PubMed  Google Scholar 

  11. F. Ferraù, A. Albani, A. Ciresi, C. Giordano, S. Cannavò, Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol. (Lausanne) 9, 358 (2018)

    Article  PubMed  Google Scholar 

  12. S. Kasayama, M. Otsuki, M. Takagi, H. Saito, S. Sumitani, H. Kouhara et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. (Oxf.) 52, 549–555 (2000)

    Article  CAS  PubMed  Google Scholar 

  13. E. Karslioglu French, A.C. Donihi, M.T. Korytkowski, Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ 365, 1114 (2019)

    Article  Google Scholar 

  14. E.A. Nyenwe, A.E. Kitabchi, The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism 65, 507–521 (2016)

    Article  CAS  PubMed  Google Scholar 

  15. A.E. Kitabchi, G.E. Umpierrez, J.M. Miles, J.N. Fisher, Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32(7), 1335–1343 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. P. Ocampo, J.M. Duarte, R. Barcia, C. Arévalo, [Association between diabetic ketoacidosis and acromegaly]. Medicina (B Aires) 78, 131–133 (2018)

    CAS  PubMed  Google Scholar 

  17. N. Yoshida et al. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute. Eur. J. Endocrinol. 169, 127–132 (2013)

    Article  CAS  PubMed  Google Scholar 

  18. P. Nasa, S. Chaudhary, P.K. Shrivastava, A. Singh, Euglycemic diabetic ketoacidosis: a missed diagnosis. World J. Diabetes 12, 514–523 (2021)

    Article  PubMed  PubMed Central  Google Scholar 

  19. N. Fleming, P.S. Hamblin, D. Story, E.I. Ekinci, Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose co-transporter 2 inhibitors. J. Clin. Endocrinol. Metab. 105, 2475–2486 (2020)

  20. E. Ferrannini, E. Muscelli, S. Frascerra, S. Baldi, A. Mari, T. Heise et al. Metabolic response to sodium-glucose co-transporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest 124, 499–508 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. A. Zaina, Y. Grober, A. Abid, E. Arad, E. Golden, S. Badarny, Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review. Endocrine 73, 65–70 (2021)

    Article  CAS  PubMed  Google Scholar 

  22. A.N. Sharma, M. Tan, E.A. Amsterdam, G.D. Singh, Acromegalic cardiomyopathy: epidemiology, diagnosis, and management. Clin. Cardiol. 41, 419–425 (2018)

    Article  PubMed  PubMed Central  Google Scholar 

  23. A. Colao, P. Marzullo, C. Di Somma, G. Lombardi, Growth hormone and the heart. Clin. Endocrinol. (Oxf.) 54, 137–154 (2001)

    Article  CAS  PubMed  Google Scholar 

  24. R. Pivonello, R.S. Auriemma, L.F. Grasso, C. Pivonello, C. Simeoli, R. Patalano et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20, 46–62 (2017)

    Article  PubMed  Google Scholar 

  25. K. Wagdy, S. Nagy, EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction. Glob. Cardiol. Sci. Pract. 2021, e202117 (2021)

    PubMed  PubMed Central  Google Scholar 

  26. M. Ragonese, A. Alibrandi, G. Di Bella, I. Salamone, S. Puglisi, O.R. Cotta et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine 47, 206–212 (2014)

    CAS  PubMed  Google Scholar 

  27. C.M. Dos Santos Silva, G.A. Lima, I.C. Volschan, I. Gottlieb, L. Kasuki, L.V. Neto, M.R. Gadelha Low risk of coronary artery disease in patients with acromegaly. Endocrine 50, 749–755 (2015)

    Article  PubMed  Google Scholar 

  28. M. Fleseriu, Insight into cardiovascular risk factors in patients with acromegaly. Endocrine 47, 1–2 (2014)

    Article  CAS  PubMed  Google Scholar 

  29. P. Maffei, F. Dassie, A. Wennberg, M. Parolin, R. Vettor, The endothelium in acromegaly. Front Endocrinol. (Lausanne) 10, 437 (2019)

    Article  PubMed  Google Scholar 

  30. C.F. Messias de Lima, M.D. Dos Santos Reis, F.W. da Silva Ramos, S. Ayres-Martins, S. Smaniotto, Growth hormone modulates in vitro endothelial cell migration and formation of capillary-like structures. Cell Biol. Int 41, 577–584 (2017)

    Article  CAS  PubMed  Google Scholar 

  31. S. Tellatin, P. Maffei, E. Osto, F. Dassie, G. Famoso, R. Montisci et al. Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy. Atherosclerosis 269, 100–105 (2018)

    Article  CAS  PubMed  Google Scholar 

  32. T.L.C. Wolters, M.G. Netea, A.R.M.M. Hermus, J.W.A. Smit, R.T. Netea-Maier, IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK. J. Mol. Endocrinol. 59, 129–139 (2017)

    Article  CAS  PubMed  Google Scholar 

  33. F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, F. Bogazzi et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 92, 4271–4277 (2007)

    Article  CAS  PubMed  Google Scholar 

  34. V.A. Ezzat, E.R. Duncan, S.B. Wheatcroft, M.T. Kearney, The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 10, 198–211 (2008)

    Article  CAS  PubMed  Google Scholar 

  35. T.L.C. Wolters, C.D.C.C. van der Heijden, N. van Leeuwen, B.T.P. Hijmans-Kersten, M.G. Netea, J.W. Smit, D.H.J. Thijssen, A. Hermus, N.P. Riksen, R. Netea-Maier, Persistent inflammation and endothelial dysfunction in patients with treated acromegaly. Endocr. Connect 8, 1553–1567 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. T.L.C. Wolters, M.G. Netea, N.P. Riksen, A.R.M.M. Hermus, R.T. Netea-Maier, Acromegaly, inflammation and cardiovascular disease: a review. Rev. Endocr. Metab. Disord. 21, 547–568 (2020)

    Article  PubMed  PubMed Central  Google Scholar 

  37. L. Boero, M. Manavela, L. Gómez Rosso, C. Insua, V. Berardi, M.C. Fornari, F. Brites, Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin. Endocrinol. (Oxf.) 70, 88–95 (2009)

    Article  CAS  PubMed  Google Scholar 

  38. F. Bonnet, A.J. Scheen, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 44, 457–464 (2018)

    Article  CAS  PubMed  Google Scholar 

  39. M. Oelze, S. Kröller-Schön, P. Welschof, T. Jansen, M. Hausding, Y. Mikhed et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 9, e112394 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  40. C. Li, J. Zhang, M. Xue, X. Li, F. Han, X. Liu et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol., 2019 18, 15 (2019)

    Article  Google Scholar 

  41. S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med 380, 347–357 (2019)

    Article  CAS  PubMed  Google Scholar 

  42. S.L. Kristensen, R. Rørth, P.S. Jhund, K.F. Docherty, N. Sattar, D. Preiss et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776–785 (2019)

    Article  CAS  PubMed  Google Scholar 

  43. D.M. Hoffman, L. Crampton, C. Sernia, T.V. Nguyen, K.K. Ho, Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J. Clin. Endocrinol. Metab. 81, 1123–1128 (1996)

    CAS  PubMed  Google Scholar 

  44. G. Johannsson, Y.B. Sverrisdóttir, L. Ellegård, P.A. Lundberg, H. Herlitz, GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J. Clin. Endocrinol. Metab. 87, 1743–1749 (2002)

    Article  CAS  PubMed  Google Scholar 

  45. P. Kamenicky, A. Blanchard, M. Frank, S. Salenave, A. Letierce, M. Azizi et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J. Clin. Endocrinol. Metab. 96, 2127–2135 (2011)

    Article  CAS  PubMed  Google Scholar 

  46. P. Kamenický, G. Mazziotti, M. Lombès, A. Giustina, P. Chanson, Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr. Rev. 35, 234–281 (2014)

    Article  PubMed  Google Scholar 

  47. H.J. Lambers Heerspink, D. de Zeeuw, L. Wie, B. Leslie, J. List, Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15, 853–862 (2013)

    Article  CAS  PubMed  Google Scholar 

  48. K.M. Hallow, G. Helmlinger, P.J. Greasley, J.J.V. McMurray, D.W. Boulton, Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes. Metab. 20, 479–487 (2018)

    Article  CAS  PubMed  Google Scholar 

  49. S.N. Cheuvront, R.W. Kenefick, Dehydration: physiology, assessment, and performance effects. Compr. Physiol. 4, 257–285 (2014)

    Article  PubMed  Google Scholar 

  50. B. Zinman, J.M. Lachin, S.E. Inzucchi, Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N. Engl. J. Med 374, 1094 (2016)

    PubMed  Google Scholar 

  51. J.J.V. McMurray, D.L. DeMets, S.E. Inzucchi, L. Køber, M.N. Kosiborod, A.M. Langkilde et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur. J. Heart Fail 21, 665–675 (2019)

    Article  CAS  PubMed  Google Scholar 

  52. K.C. Leung, N. Doyle, M. Ballesteros, M.J. Waters, K.K. Ho, Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712–4720 (2000)

    CAS  PubMed  Google Scholar 

  53. M.A. Nauck, Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des. Dev. Ther. 8, 1335–1380 (2014)

    Article  Google Scholar 

  54. M. Alatrach, N. Laichuthai, R. Martinez, C. Agyin, A.M. Ali, H. Al-Jobori et al. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes 69, 681–688 (2020)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. W.T. Cefalu, L.A. Leiter, K.H. Yoon, P. Arias, L. Niskanen, J. Xie et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382, 941–950 (2013)

    Article  CAS  PubMed  Google Scholar 

  56. N. Unger, B. Ueberberg, S. Schulz, W. Saeger, K. Mann, S. Petersenn, Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues. Exp. Clin. Endocrinol. Diabetes 120, 482–489 (2012)

    Article  CAS  PubMed  Google Scholar 

  57. S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14, 552–561 (2018)

    Article  PubMed  PubMed Central  Google Scholar 

  58. M.R. Gadelha, L.E. Wildemberg, M.D. Bronstein, F. Gatto, D. Ferone, Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20, 100–108 (2017)

    Article  CAS  PubMed  Google Scholar 

  59. R. Baldelli, C. Battista, F. Leonetti, M.R. Ghiggi, M.C. Ribaudo, A. Paoloni et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin. Endocrinol. (Oxf.) 59, 492–499 (2003)

    Article  CAS  PubMed  Google Scholar 

  60. G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs rochron glucose homeostasis: a meta-analysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500–1508 (2009)

    Article  CAS  PubMed  Google Scholar 

  61. C.L. Ronchi et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J. Endocrinol. Invest 26, 533–538 (2003)

    Article  CAS  PubMed  Google Scholar 

  62. C.L. Ronchi, V. Varca, P. Beck-Peccoz, E. Orsi, F. Donadio, A. Baccarelli, C. Giavoli et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J. Clin. Endocrinol. Metab. 91, 121–128 (2006)

    Article  CAS  PubMed  Google Scholar 

  63. R.A. Rizza, L.J. Mandarino, J. Genest, B.A. Baker, J.E. Gerich, Production of insulin resistance by hyperinsulinaemia in man. Diabetologia, 1985 28, 70–75 (1985)

    CAS  Google Scholar 

  64. A. Colao, R.S. Auriemma, S. Savastano, M. Galdiero, L.F. Grasso, G. Lombardi, R. Pivonello, Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J. Clin. Endocrinol. Metab. 94, 2907–2914 (2009)

    Article  CAS  PubMed  Google Scholar 

  65. G. Mazziotti et al. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur. J. Endocrinol. 164, 341–347 (2011)

    Article  CAS  PubMed  Google Scholar 

  66. A. Giustina, G. Mazziotti, F. Maffezzoni, V. Amoroso, A. Berruti. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig. Drugs. 23, 1619–1635 (2014).

  67. A. Colao, C. De Block, M.S. Gaztambide, S. Kumar, J. Seufert, F.F. Casanueva, Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17, 180–186 (2014)

    Article  CAS  PubMed  Google Scholar 

  68. L. Hansen, B. Hartmann, T. Bisgaard, H. Mineo, P.N. Jørgensen, J.J. Holst, Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am. J. Physiol. Endocrinol. Metab. 278, E1010–E1018 (2000)

    Article  CAS  PubMed  Google Scholar 

  69. M. Fleseriu, E. Rusch, E.B. Geer, ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55, 247–255 (2017)

    Article  CAS  PubMed  Google Scholar 

  70. M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875–884 (2014)

    Article  CAS  PubMed  Google Scholar 

  71. A. Colao et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. I. Shimon, Z. Adnan, A. Gorshtein, L. Baraf, N. Saba Khazen, M. Gershinsky et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62, 448–455 (2018)

    Article  CAS  PubMed  Google Scholar 

  73. H. Lasolle, A. Ferriere, A. Vasiljevic, S. Eimer, M.L. Nunes, A. Tabarin, Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr. Connect 8, 1383–1394 (2019)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. M.A. Bredella, M. Schorr, L.E. Dichtel, A.V. Gerweck, B.J. Young, W.W. Woodmansee et al. Body composition and ectopic lipid changes with biochemical control of acromegaly. J. Clin. Endocrinol. Metab. 102, 4218–4225 (2017)

    Article  PubMed  PubMed Central  Google Scholar 

  75. M. Stelmachowska-Banaś, I. Czajka-Oraniec, A. Tomasik, W. Zgliczyński, Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25, 180–190 (2022)

    Article  PubMed  Google Scholar 

  76. C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur. J. Endocrinol. 169, 99–108 (2013)

    Article  CAS  PubMed  Google Scholar 

  77. C.E. Higham, T.T. Chung, J. Lawrance, W.M. Drake, P.J. Trainer, Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.) 71, 86–91 (2009)

    Article  CAS  PubMed  Google Scholar 

  78. T. Brue, A. Lindberg, A. Jan van der Lely, A.C. Akerblad, M. Koltowska-Häggström, R. Gomez et al. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 63, 563–572 (2019)

    Article  CAS  PubMed  Google Scholar 

  79. M. Droste, J. Domberg, M. Buchfelder, K. Mann, A. Schwanke, G. Stalla, C.J. Strasburger, Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur. J. Endocrinol. 171, 59–68 (2014)

    Article  CAS  PubMed  Google Scholar 

  80. J.L. Kerr, E.M. Timpe, K.A. Petkewicz, Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann. Pharmacother. 44, 1777–1785 (2010)

    Article  CAS  PubMed  Google Scholar 

  81. R.E. Scranton, J.M. Gaziano, D. Rutty, M. Ezrokhi, A. Cincotta, A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr. Disord. 7, 3 (2007)

    Article  PubMed  PubMed Central  Google Scholar 

  82. H. Rau, P.H. Althoff, K. Schmidt, K. Badenhoop, K.H. Usadel, Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. Clin. Investig. 71, 372–378 (1993)

    Article  CAS  PubMed  Google Scholar 

  83. L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011)

    Article  CAS  PubMed  Google Scholar 

  84. Z. Adnan, Sodium glucose co-transporter inhibitors in patients with acromegaly and diabetes. Trends Endocrinol. Metab. 30, 77–79 (2019)

    Article  CAS  PubMed  Google Scholar 

  85. A.F. Da Rocha, P.S. Pereira Junior, G.S. Calefi, G.F. Marquezine, H.K. Morimoto, T.L. Mazzuco et al. Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin. Endocrine 73, 325–330 (2021)

    Article  PubMed  Google Scholar 

  86. N. Prencipe, F. Bioletto, C. Bona, F. Gatti, S. Grottoli, Diabetic ketoacidosis in acromegaly: a case study- somatostatin analogs adverse event or disease complication? Acta Diabetol. 57, 491–493 (2020)

    Article  CAS  PubMed  Google Scholar 

  87. E. Ferrannini, Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 7–38 (2017)

    Article  Google Scholar 

  88. J.B. Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43, 487–493 (2020)

    Article  CAS  PubMed  Google Scholar 

  89. F. Cosentino, P.J. Grant, V. Aboyans, C.J. Bailey, A. Ceriello, V. Delgado et al. 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255–323 (2020)

    Article  PubMed  Google Scholar 

Download references

Funding

This article did not receive any specific grant from any public, commercial, or not-for-profit funding agency.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Clalit Medical Health Care Services, Tel Aviv, Haifa and Western Galilee District, Israel

    Adnan Zaina, Elena Golden, Eldad Arad & Ali Abid

  2. Bar-Ilan Faculty of Medicine, Safed, Israel

    Adnan Zaina

  3. Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy

    Nunzia Prencipe, Alessandro Maria Berton & Ezio Ghigo

  4. Division of Cardiology, Zvulon Medical Center, Clalit Medical Health Care, Services, Tel Aviv, Haifa and Western Galilee District, Israel

    Jeryes Shehadeh

  5. Department of Internal Medicine, Carmel Medical Center, Haifa, Israel

    Sameer Kassem

  6. Technion, Faculty of Medicine, Haifa, Israel

    Sameer Kassem

Authors
  1. Adnan Zaina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nunzia Prencipe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Golden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Maria Berton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eldad Arad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ali Abid
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeryes Shehadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sameer Kassem
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ezio Ghigo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adnan Zaina.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaina, A., Prencipe, N., Golden, E. et al. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients. Endocrine 80, 491–499 (2023). https://doi.org/10.1007/s12020-023-03352-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-023-03352-4

Search

Navigation